J. Litton

H. Burstein, N. Turner, J. Litton, 2019, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

Determinants of Response to Talazoparib in Patients with HER2-Negative, Germline BRCA1/2-Mutated Breast Cancer

H. Rugo, J. Hopkins, Miguel Martín, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

A phase II study of talimogene laherparepvec for patients with inoperable locoregional recurrence of breast cancer

Diane D. Liu, M. Ross, N. Ibrahim, 2021, Scientific Reports.

Incidence of germline BRCA mutation in patients with ER-low positive/PR negative/HER-2 neu negative tumors.

V. Valero, I. Bedrosian, B. Arun, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Rapid Breast Cancer Disease Progression Following Cyclin Dependent Kinase 4 and 6 Inhibitor Discontinuation

P. Brown, V. Valero, N. Ibrahim, 2017, Journal of Cancer.

Patient-reported outcomes (PROs) in patients (pts) with advanced breast cancer (aBC) and a germline BRCA1/2 mutation (gBRCAm) receiving talazoparib (TALA) vs physician’s choice chemotherapy treatment (PCT): a focus on the EMBRACA HR+/HER2- subpopulation

H. Rugo, J. Litton, S. Hurvitz, 2018, The Breast.

Prevention of everolimus-related stomatitis in women with hormone receptor-positive, HER2-negative metastatic breast cancer using dexamethasone mouthwash (SWISH): a single-arm, phase 2 trial.

M. Chambers, H. Rugo, J. Beck, 2017, The Lancet. Oncology.

Exposure‐Safety Analyses of Talazoparib in Patients With Advanced Breast Cancer and Germline BRCA1/2 Mutations in the EMBRACA and ABRAZO Trials

I. C. Tudor, A. Czibere, J. Litton, 2020, Journal of clinical pharmacology.

Evaluating the NCCN Clinical Criteria for Recommending BRCA1 and BRCA2 Genetic Testing in Patients With Breast Cancer.

Diane D. Liu, B. Arun, M. Daniels, 2017, Journal of the National Comprehensive Cancer Network : JNCCN.

Effectiveness of alternating mammography and magnetic resonance imaging for screening women with deleterious BRCA mutations at high risk of breast cancer

G. Hortobagyi, Ying Yuan, B. Arun, 2011, Cancer.

Tamoxifen therapy for patients with breast cancer

G. Hortobagyi, A. Buzdar, A. González-Angulo, 2013, The Lancet.

Fertility preservation in women with breast cancer: challenges and opportunities.

J. Litton, T. Woodard, 2013, Oncology.

Talazoparib in Patients with a Germline BRCA‐Mutated Advanced Breast Cancer: Detailed Safety Analyses from the Phase III EMBRACA Trial

H. Rugo, I. C. Tudor, J. Chakrabarti, 2019, The oncologist.

Exposure-safety analyses in breast cancer patients with germline BRCA1/2 mutations receiving talazoparib (TALA) in EMBRACA and ABRAZO trials.

I. C. Tudor, N. Turner, A. Czibere, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Exposure-efficacy progression-free survival (PFS) analyses of breast cancer patients with germline BRCA1/2 mutations receiving talazoparib in the phase III EMBRACA trial.

I. C. Tudor, A. Czibere, J. Litton, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation

W. Eiermann, H. Rugo, I. C. Tudor, 2018, The New England journal of medicine.

Talazoparib Exposure‐Efficacy Analysis in Patients With Advanced Breast Cancer and Germline BRCA1/2 Mutations in the EMBRACA Trial

I. C. Tudor, A. Czibere, J. Litton, 2020, Journal of clinical pharmacology.

Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline BRCA Pathogenic Variant.

K. Hess, V. Valero, N. Ibrahim, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Analysis of germline BRCA1/2 mutated (gBRCAmut) hormone receptor-positive (HR+) and triple negative breast cancer (TNBC) treated with talazoparib (TALA).

W. Eiermann, H. Rugo, I. C. Tudor, 2018 .

Ten-year recurrence rates in young women with breast cancer by locoregional treatment approach.

W. Woodward, T. Buchholz, F. Meric-Bernstam, 2009, International journal of radiation oncology, biology, physics.

BRCA mutations in women with inflammatory breast cancer

N. Ueno, B. Arun, J. Litton, 2018, Cancer.

Abstract 4970: Oxidative phosphorylation as a target in triple negative breast cancer therapy

C. Perou, G. Hortobagyi, V. Valero, 2017 .

Cancer and Pregnancy

J. Litton, 2019, Holland‐Frei Cancer Medicine.

Neoadjuvant talazoparib (TALA) for operable breast cancer patients with a BRCA mutation (BRCA

K. Hess, N. Ibrahim, M. Scoggins, 2018 .

P1.01A phase 3 study of the oral PARP inhibitor talazoparib (BMN 673) in BRCA mutation subjects with advanced breast cancer (EMBRACA)

W. Eiermann, H. Rugo, M. Martín, 2015 .

Significant increased recurrence rates among breast cancer patients with HER2-positive, T1a,bN0M0 tumors.

D. Larsimont, M. Piccart, G. Hortobagyi, 2009 .

Outcomes of children exposed in utero to chemotherapy for breast cancer

G. Hortobagyi, V. Valero, R. Theriault, 2014, Breast Cancer Research.

Pregnancy following breast cancer using assisted reproduction and its effect on long-term outcome

J. Litton, T. Woodard, 2016 .

Reply to D. Crivellari et al.

R. Theriault, J. Litton, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pregnancy during or after breast cancer diagnosis: what do we know and what do we need to know?

R. Theriault, J. Litton, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prevalence of BRCA1 and BRCA2 mutations in women diagnosed with ductal carcinoma in situ.

G. Hortobagyi, H. Kuerer, F. Meric-Bernstam, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Hereditary breast cancer syndromes and genetic testing

B. Arun, J. Litton, T. Rich, 2015, Journal of surgical oncology.

High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types.

E. Jonasch, N. Rashid, L. Voorwerk, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

Two may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancer

D. Cescon, B. Vincent, S. Adams, 2019, npj Breast Cancer.

Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide GP2 vaccine in breast cancer patients to prevent recurrence

J. Murray, E. Mittendorf, G. Peoples, 2016, Oncotarget.

Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial.

C. Isaacs, Bing-he Xu, F. André, 2014, The Lancet. Oncology.

Prospective, randomized, single-blinded, multi-center phase II trial of two HER2 peptide vaccines, GP2 and AE37, in breast cancer patients to prevent recurrence

J. Murray, E. Mittendorf, G. Peoples, 2020, Breast Cancer Research and Treatment.

Current Landscape of Immunotherapy in Breast Cancer: A Review.

G. Hortobagyi, B. Vincent, S. Adams, 2019, JAMA oncology.

Effects of HLA status and HER2 status on outcomes in breast cancer patients at risk for recurrence - Implications for vaccine trial design.

J. Murray, E. Mittendorf, G. Peoples, 2018, Clinical immunology.

Results of a Phase Ib Trial of Combination Immunotherapy with a CD8+ T Cell Eliciting Vaccine and Trastuzumab in Breast Cancer Patients

N. Ibrahim, E. Mittendorf, G. Peoples, 2017, Annals of Surgical Oncology.

PD-L1 Expression in Triple-Negative Breast Cancer

P. Sharma, F. Meric-Bernstam, Yun Wu, 2014, Cancer Immunology Research.

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer

H. Rugo, S. Adams, A. Cimino-Mathews, 2021, Journal for ImmunoTherapy of Cancer.

PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression

G. Hortobagyi, M. Hung, Seung-Oe Lim, 2017, Clinical Cancer Research.

Metformin Promotes Antitumor Immunity via Endoplasmic-Reticulum-Associated Degradation of PD-L1.

W. Symmans, M. Hung, Seung-Oe Lim, 2018, Molecular cell.

Integrating poly(ADP-ribose) polymerase (PARP) inhibitors in the treatment of early breast cancer

J. Litton, H. Garber, 2019, Current opinion in oncology.

Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation

G. Mills, E. Winer, G. Hortobagyi, 2019, Breast Cancer Research.

Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab

K. Hess, V. Valero, N. Ibrahim, 2017, JAMA oncology.

Clinical outcomes based on multigene profiling in metastatic breast cancer patients

G. Mills, F. Meric-Bernstam, A. Sahin, 2016, Oncotarget.

NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020.

S. Friedman, K. Offit, S. Buys, 2020, Journal of the National Comprehensive Cancer Network : JNCCN.

Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutations

Diane D. Liu, G. Hortobagyi, F. Meric-Bernstam, 2011, Breast Cancer Research and Treatment.

Cancers Associated with Brca1 and Brca2 Mutations Other than Breast and Ovarian Cancers Associated with Brca1 and Brca2 Mutations Other than Breast and Ovarian

B. Arun, S. Peterson, J. Litton, 2022 .

A Population of Heterogeneous Breast Cancer Patient-Derived Xenografts Demonstrate Broad Activity of PARP Inhibitor in BRCA1/2 Wild-Type Tumors

G. Mills, F. Meric-Bernstam, Ken Chen, 2017, Clinical Cancer Research.

High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller.

Funda Meric-Bernstam, Kristine R Broglio, Denis Larsimont, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype?

F. Meric-Bernstam, N. Ueno, A. González-Angulo, 2015, Oncotarget.

Local-regional control according to surrogate markers of breast cancer subtypes and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast conserving therapy

K. Hunt, T. Buchholz, K. Hoffman, 2009, Breast Cancer Research.

Genetic/familial high-risk assessment: breast and ovarian, version 1.2014.

S. Friedman, K. Offit, S. Buys, 2014, Journal of the National Comprehensive Cancer Network : JNCCN.

Phase Ib Dose Expansion and Translational Analyses of Olaparib in Combination with Capivasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian Cancer

G. Mills, A. Jazaeri, A. Sood, 2021, Clinical Cancer Research.

Effect of metformin on survival outcomes in diabetic patients with triple receptor‐negative breast cancer

G. Hortobagyi, F. Meric-Bernstam, A. González-Angulo, 2012, Cancer.

Outcome of metastatic breast cancer in selected women with or without deleterious BRCA mutations

G. Hortobagyi, V. Valero, N. Ibrahim, 2013, Clinical & Experimental Metastasis.

Phase 1b dose expansion and translational analyses of olaparib in combination with the oral AKT inhibitor capivasertib in recurrent endometrial, triple negative breast, and ovarian, primary peritoneal, or fallopian tube cancer

G. Mills, A. Jazaeri, R. Coleman, 2021, medRxiv.

Incidental germline variants in 1000 advanced cancers on a prospective somatic genomic profiling protocol.

Ann M. Bailey, Yuan Qi, Y. Qi, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Early onset HER2‐positive breast cancer is associated with germline TP53 mutations

Diane D. Liu, O. Olopade, G. Hortobagyi, 2012, Cancer.

The implications of genetic testing on radiotherapy decisions: a guide for radiation oncologists.

W. Woodward, N. Riaz, D. Higginson, 2019, International journal of radiation oncology, biology, physics.

Response to neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers: a single-institution experience.

Funda Meric-Bernstam, Lajos Pusztai, Diane D. Liu, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Identification of biomarkers of response to preoperative talazoparib monotherapy in treatment naïve gBRCA+ breast cancers

Jeffrey T. Chang, Jason B. White, Fei Yang, 2022, npj Breast Cancer.

Pathological complete response in breast cancer patients receiving anthracycline and taxane-based neoadjuvant chemotherapy: Evaluating the effect of race/ethnicity

G. Hortobagyi, C. Hudis, V. Valero, 2011 .

Prospective Evaluation of Universal BRCA Testing for Women With Triple-Negative Breast Cancer

B. Arun, K. Lu, K. I. Muse, 2020, JNCI cancer spectrum.

Incidence and Outcome of BRCA Mutations in Unselected Patients with Triple Receptor-Negative Breast Cancer

G. Mills, G. Hortobagyi, K. Do, 2011, Clinical Cancer Research.

Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer†.

G. Mills, G. Hortobagyi, L. Pusztai, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Prognostic value of the trichorhinophalangeal syndrome-1 (TRPS-1), a GATA family transcription factor, in early-stage breast cancer.

G. Hortobagyi, J. Murray, A. Sahin, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Clinical Characteristics and Cause of Death Among Hospitalized Decedents With Cancer and COVID-19

Hannah C. Beird, J. Weinstein, P. Scheet, 2022, Mayo Clinic Proceedings.

Synthetic Lethality of PARP Inhibitors in Combination with MYC Blockade Is Independent of BRCA Status in Triple-Negative Breast Cancer.

Xian Chen, Jing Wang, K. Hunt, 2018, Cancer research.

The impact of pregnancy on breast cancer outcomes in women ≤35 years

W. Woodward, T. Buchholz, R. Theriault, 2009, Cancer.

Breast cancer in adolescents and young adults

A. Bleyer, C. Anders, K. Ruddy, 2018, Pediatric blood & cancer.

Case control study of women treated with chemotherapy for breast cancer during pregnancy as compared with nonpregnant patients with breast cancer.

G. Hortobagyi, H. Kuerer, R. Theriault, 2013, The oncologist.

Wound complications from surgery in pregnancy-associated breast cancer (PABC).

G. Hortobagyi, H. Kuerer, G. Babiera, 2010, Breast disease.

Systemic Treatment During Pregnancy

R. Theriault, J. Litton, 2010 .

A phase 3 trial comparing talazoparib, an oral PARP inhibitor, to physician’s choice of therapy in patients with advanced breast cancer and a germline BRCA mutation: EMBRACA subgroups by age

W. Eiermann, H. Rugo, I. C. Tudor, 2018, The Breast.

Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2015.

Kenneth Offit, Elizabeth Swisher, Seema Khan, 2016, Journal of the National Comprehensive Cancer Network : JNCCN.

Breast cancer before age 40 years.

A. Bleyer, C. Anders, J. Litton, 2009, Seminars in oncology.

High incidence of germline BRCA mutation in patients with ER low‐positive/PR low‐positive/HER‐2 neu negative tumors

V. Valero, I. Bedrosian, B. Arun, 2015, Cancer.

Breast cancer in the young: role of the geneticist.

K. I. Muse, J. Litton, A. Woodson, 2013, Journal of thoracic disease.

Evaluating breast cancer risk with genome-wide association studies: is this approach patient ready?

A. González-Angulo, J. Litton, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

ACCURACY OF THE BRCAPRO RISK ASSESSMENT MODEL IN MALES PRESENTING TO MD ANDERSON FOR BRCA TESTING

B. Arun, J. Litton, S. Hashmi, 2012 .

Adjuvant versus neoadjuvant chemotherapy in triple-negative breast cancer patients with BRCA mutations

G. Hortobagyi, H. Kuerer, B. Arun, 2018, Breast Cancer Research and Treatment.

Endocrine Treatment and Targeted Therapy for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer: ASCO Guideline Update

M. Somerfield, L. Fallowfield, H. Rugo, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Development of the PARP inhibitor talazoparib for the treatment of advanced BRCA1 and BRCA2 mutated breast cancer

T. Yap, J. Litton, E. Hobbs, 2021, Expert opinion on pharmacotherapy.

Revisiting the definition of estrogen receptor positivity in HER2-negative primary breast cancer

L. Pusztai, A. Sahin, N. Ueno, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Systemic Treatment Strategies for Patients with Hereditary Breast Cancer Syndromes.

B. Arun, J. Litton, A. Parkes, 2017, The oncologist.

A phase 3, open-label, randomized, parallel, 2-arm international study of the oral PARP inhibitor talazoparib (BMN 673) in BRCA mutation subjects with locally advanced and/or metastatic breast cancer (EMBRACA).

W. Eiermann, H. Rugo, Y. Im, 2015 .

Incidence of brain metastases as a first site of recurrence among women with triple receptor–negative breast cancer

G. Hortobagyi, T. Buchholz, A. González-Angulo, 2012, Cancer.

Prediction of pathologic complete response to neoadjuvant systemic therapy in triple negative breast cancer using deep learning on multiparametric MRI

Tanya W. Moseley, Miral M Patel, Jason B. White, 2023, Scientific Reports.

Prevalence of incidental actionable germline mutations in 1,000 advanced cancer patients on a prospective somatic genomic profiling program.

G. Mills, Y. Qi, L. Strong, 2015 .

Imaging , Diagnosis , Prognosis Incidence and Outcome of BRCA Mutations in Unselected Patients with Triple Receptor-Negative Breast Cancer

G. Mills, G. Hortobagyi, K. Do, 2011 .

Contralateral prophylactic mastectomy rate and predictive factors among patients with breast cancer who underwent multigene panel testing for hereditary cancer

H. Kuerer, I. Bedrosian, B. Arun, 2018, Cancer medicine.

Genotype in BRCA‐associated Breast Cancers

Funda Meric-Bernstam, G. Hortobagyi, F. Meric-Bernstam, 2013, The breast journal.

A phase II study of Mirvetuximab Soravtansine in triple-negative breast cancer

Jason B. White, J. Stec, W. Symmans, 2020, Investigational New Drugs.

Current Approach to Breast Cancer Risk Reduction for Women with Hereditary Predispositions to Breast Cancer

J. Litton, Grace Tran, M. Helm, 2016, Current Breast Cancer Reports.

Predictors that Influence Contralateral Prophylactic Mastectomy Election Among Women with Ductal Carcinoma In Situ Who Were Evaluated for BRCA Genetic Testing

G. Hortobagyi, H. Kuerer, B. Arun, 2014, Annals of Surgical Oncology.

Reduction of cancer-related fatigue with dexamethasone: a double-blind, randomized, placebo-controlled trial in patients with advanced cancer.

Eduardo Bruera, Lisa Massie, Sriram Yennurajalingam, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

USP-11 as a Predictive and Prognostic Factor Following Neoadjuvant Therapy in Women With Breast Cancer

Diane D. Liu, G. Hortobagyi, L. Pusztai, 2013, Cancer journal.

Variants in the ATM Gene Associated with a Reduced Risk of Contralateral Breast Cancer: Concannon P, Haile RW, Børresen-Dale A-L, et al (Univ of Virginia, Charlottesville; Univ of Southern California; Univ of Oslo, Norway; et al) Cancer Res 68:6486-6491, 2008§

J. Litton, 2009 .

SETER/PR: a robust 18-gene predictor for sensitivity to endocrine therapy for metastatic breast cancer

A. Viale, C. Sotiriou, W. Fraser Symmans, 2019, npj Breast Cancer.

Abstract GS6-07: EMBRACA: A phase 3 trial comparing talazoparib, an oral PARP inhibitor, to physician's choice of therapy in patients with advanced breast cancer and a germline BRCA mutation

W. Eiermann, I. C. Tudor, Y. Im, 2018 .

The Biology of the HER Family and Her2/neu Directed-Antibody Therapy

G. Hortobagyi, J. Litton, 2010 .

Utility of oncotype DX risk estimates in clinically intermediate risk hormone receptor‐positive, HER2‐normal, grade II, lymph node‐negative breast cancers

G. Hortobagyi, L. Pusztai, S. Krishnamurthy, 2010, Cancer.

Triple-Negative Breast Cancer Is Not a Contraindication for Breast Conservation

W. Woodward, K. Hunt, F. Meric-Bernstam, 2011, Annals of Surgical Oncology.

Clinical application of breast cancer risk assessment models.

B. Arun, K. Ready, J. Litton, 2010, Future oncology.

A model combining pretreatment MRI radiomic features and tumor-infiltrating lymphocytes to predict response to neoadjuvant systemic therapy in triple-negative breast cancer.

Jason B. White, J. Hazle, V. Valero, 2022, European journal of radiology.

Breast Cancer Before 40

A. Bleyer, C. Anders, K. Ruddy, 2017 .

Age at diagnosis and distant metastasis in breast cancer - A surprising inverse relationship

J. Litton, 2015 .

Breast cancer presentation and diagnostic delays in young women

J. Litton, 2014 .

Breast Cancer and Fertility

J. Litton, 2012, Current Treatment Options in Oncology.

Age and survival estimates in patients who have node-negative T1ab breast cancer by breast cancer subtype.

W. Woodward, G. Hortobagyi, F. Meric-Bernstam, 2011, Clinical breast cancer.

Multifocal breast cancer in women ≤35 years old

G. Hortobagyi, A. González-Angulo, B. Arun, 2007, Cancer.

ICONIC: Biologic and clinical activity of first in class ICOS agonist antibody JTX-2011 +/- nivolumab (nivo) in patients (pts) with advanced cancers.

H. Hirsch, F. Meric-Bernstam, G. Gibney, 2018 .

PD-L 1 Expression in Triple-Negative Breast Cancer

P. Sharma, F. Meric-Bernstam, Yun Wu, 2014 .

Multidisciplinary Considerations in the Implementation of the Findings from the American College of Surgeons Oncology Group (ACOSOG) Z0011 Study: A Practice-Changing Trial

G. Hortobagyi, M. Ross, H. Kuerer, 2011, Annals of Surgical Oncology.

Breast Cancer Diagnosis during Pregnancy

R. Theriault, A. González-Angulo, J. Litton, 2009, Women's health.

Safety of pregnancy following breast cancer diagnosis: A meta-analysis of 14 studies

J. Litton, R. Theriault, 2011 .

A pilot study of neoadjuvant talazoparib for early-stage breast cancer patients with a BRCA mutation

G. Mills, K. Hess, V. Valero, 2016 .

Progression-free survival (PFS) and toxicities of palbociclib in a geriatric population

D. Tripathy, J. Litton, M. Karuturi, 2019, Breast Cancer Research and Treatment.

Breast cancer, BRCA mutations, and attitudes regarding pregnancy and preimplantation genetic diagnosis.

G. Hortobagyi, R. Theriault, L. Schover, 2014, The oncologist.

Abstract OT1-03-16: EMBRACA: A phase 3, open-label, randomized, parallel, 2-arm international study of the oral PARP inhibitor talazoparib (BMN 673) versus physician's choice in BRCA mutation subjects with locally advanced and/or metastatic breast cancer

W. Eiermann, Y. Im, M. Martín, 2016 .

Incidence of brain metastases as a first site of recurrence among women with triple receptor-negative breast cancer.

G. Hortobagyi, T. Buchholz, A. González-Angulo, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Impact of body mass index on survival outcome among women with early stage triple-negative breast cancer.

G. Hortobagyi, T. Buchholz, A. González-Angulo, 2012, Clinical breast cancer.

Pathologic complete response to neoadjuvant chemotherapy with trastuzumab predicts for improved survival in women with HER2-overexpressing breast cancer.

W. Woodward, G. Hortobagyi, H. Kuerer, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Immune Phenotype and Response to Neoadjuvant Therapy in Triple-Negative Breast Cancer

Jeffrey T. Chang, Jason B. White, G. Hortobagyi, 2021, Clinical Cancer Research.

Oestrogen receptor coactivator AIB 1 is a marker of tamoxifen bene fi t in postmenopausal breast cancer

W. Woodward, G. Hortobagyi, F. Meric-Bernstam, 2013 .

Prognostic Factors in Patients with Metastatic Breast Cancer with Bone‐Only Metastases

G. Hortobagyi, C. Warneke, J. Litton, 2018, The oncologist.

Biologic features and prognosis of ductal carcinoma in situ are not adversely impacted by initial large body mass

H. Kuerer, G. Babiera, K. Hunt, 2012, Breast Cancer Research and Treatment.

Evaluation of BRCAPRO Risk Assessment Model in Patients with Ductal Carcinoma In situ Who Underwent Clinical BRCA Genetic Testing

H. Kuerer, B. Arun, K. I. Muse, 2016, Front. Genet..

Clinicopathologic factors associated with involved margins after breast-conserving surgery for invasive lobular carcinoma.

K. Hunt, R. Hwang, A. Sahin, 2010, Clinical breast cancer.

Early ultrasound evaluation identifies excellent responders to neoadjuvant systemic therapy among patients with triple‐negative breast cancer

Tanya W. Moseley, Jason B. White, V. Valero, 2021, Cancer.

Presentation, Management and Outcome of 32 Patients with Pregnancy-Associated Breast Cancer: A Matched Controlled Study: Halaska MJ, Pentheroudakis G, Strnad P, et al (Charles Univ in Prague, Czech Republic; Ioannina Univ Hosp, Greece; et al) Breast J 15:461-467, 2009 §

J. Litton, 2010 .

Aromatase inhibitors and breast cancer prevention

P. Brown, G. Hortobagyi, B. Arun, 2012, Expert opinion on pharmacotherapy.

Blocking c-Met and EGFR reverses acquired resistance of PARP inhibitors in triple-negative breast cancer.

Jeffrey T. Chang, K. Hess, G. Hortobagyi, 2020, American journal of cancer research.

Receptor status change from primary to residual breast cancer after neoadjuvant chemotherapy and analysis of survival outcomes.

W. Woodward, G. Hortobagyi, V. Valero, 2015, Clinical breast cancer.

Clinical features associated with a favorable outcome following neoadjuvant chemotherapy in women with localized breast cancer aged 35 years or younger

Terry L. Smith, G. Hortobagyi, V. Valero, 2008, Journal of Cancer Research and Clinical Oncology.

Molecular characterization and prospective evaluation of pathological response and outcomes with neoadjuvant therapy in metaplastic triple-negative breast cancer.

Jeffrey T. Chang, Jason B. White, G. Hortobagyi, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Immunologic responses in triple-negative breast cancer patients in a randomized phase IIb trial of nelipepimut-S plus trastuzumab versus trastuzumab alone to prevent recurrence.

E. Mittendorf, G. Peoples, J. Litton, 2019, Journal of Clinical Oncology.

Delineating longitudinal patterns of response to neoadjuvant systemic therapy (NAST) in triple-negative breast cancer (TNBC): Profiling results from a randomized, TNBC enrolling trial to confirm molecular profiling improves survival (ARTEMIS; NCT02276443).

Jeffrey T. Chang, W. Symmans, G. Rauch, 2019, Journal of Clinical Oncology.

Precision neoadjuvant therapy (P-NAT): A planned interim analysis of a randomized, TNBC enrolling trial to confirm molecular profiling improves survival (ARTEMIS).

K. Hess, W. Symmans, G. Rauch, 2018 .

Subgroup analysis of nelipepimut-S plus GM-CSF combined with trastuzumab versus trastuzumab alone to prevent recurrences in patients with high-risk, HER2 low-expressing breast cancer.

E. Mittendorf, A. Philips, G. Peoples, 2021, Clinical immunology.

Bisphosphonates and pathologic complete response to taxane‐ and anthracycline‐based neoadjuvant chemotherapy in patients with breast cancer

G. Hortobagyi, V. Valero, A. González-Angulo, 2012, Cancer.

EMBRACA: Comparison of efficacy and safety of talazoparib (TALA) and physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC), a germline BRCA1/2 mutation (gBRCAm), and prior platinum treatment.

W. Eiermann, H. Rugo, I. C. Tudor, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Expanded analysis of secondary germline findings from matched tumor/normal sequencing identifies additional clinically significant mutations.

Yuan Qi, G. Mills, Y. Qi, 2019, JCO precision oncology.

Neoadjuvant Pertuzumab‐containing Regimens Improve Pathologic Complete Response Rates in Stage II to III HER‐2/neu‐positive Breast Cancer: A Retrospective, Single Institution Experience

Takeo Fujii, Kenneth R. Hess, Elizabeth A. Mittendorf, 2018, Clinical breast cancer.

Comparative Effectiveness of an mTOR-Based Systemic Therapy Regimen in Advanced, Metaplastic and Nonmetaplastic Triple-Negative Breast Cancer.

K. Hess, G. Hortobagyi, V. Valero, 2018, The oncologist.

Predictive factors for BRCA1/BRCA2 mutations in women with ductal carcinoma in situ

G. Hortobagyi, H. Kuerer, F. Meric-Bernstam, 2012, Cancer.

Use of ACE Inhibitors and Angiotensin Receptor Blockers and Primary Breast Cancer Outcomes

G. Hortobagyi, S. Giordano, A. González-Angulo, 2013, Journal of Cancer.

Comprehensive profiling of androgen receptor-positive (AR+) triple-negative breast cancer (TNBC) patients (pts) treated with standard neoadjuvant therapy (NAT) +/- enzalutamide.

W. Symmans, V. Valero, G. Rauch, 2020 .

Abstract OT2-06-01: A phase-2 trial of neoadjuvant alpelisib and nab-paclitaxel in anthracycline refractory triple negative breast cancers with PIK3CA or PTEN alterations

K. Hess, I. Wistuba, G. Rauch, 2020 .

Final analysis of nelipepimut-S plus GM-CSF with trastuzumab versus trastuzumab alone to prevent recurrences in high-risk, HER2 low-expressing breast cancer: A prospective, randomized, blinded, multicenter phase IIb trial.

E. Mittendorf, G. Peoples, J. Litton, 2019, Journal of Clinical Oncology.

Primary analysis of the prospective, randomized, phase II trial of GP2+GM-CSF vaccine versus GM-CSF alone administered in the adjuvant setting to high-risk breast cancer patients.

J. Murray, E. Mittendorf, G. Peoples, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II Randomized Study of Ixabepilone Versus Observation in Patients With Significant Residual Disease After Neoadjuvant Systemic Therapy for HER2-Negative Breast Cancer.

G. Hortobagyi, V. Valero, N. Ibrahim, 2015, Clinical breast cancer.

Predictors that Influence Election of Contralateral Prophylactic Mastectomy among Women with Ductal Carcinoma in Situ who are BRCA-Negative

H. Kuerer, D. Tripathy, B. Arun, 2015, Journal of Cancer.

Points to consider: is there evidence to support BRCA1/2 and other inherited breast cancer genetic testing for all breast cancer patients? A statement of the American College of Medical Genetics and Genomics (ACMG)

G. Jarvik, A. L. La Spada, T. Pal, 2019, Genetics in Medicine.

Stomatitis associated with mammalian target of rapamycin inhibition: A review of pathogenesis, prevention, treatment, and clinical implications for oral practice in metastatic breast cancer.

M. Chambers, H. Rugo, J. Litton, 2018, Journal of the American Dental Association.

Targeting chemotherapy resistance in mesenchymal triple-negative breast cancer: a phase II trial of neoadjuvant angiogenic and mTOR inhibition with chemotherapy

Jeffrey T. Chang, G. Hortobagyi, W. Symmans, 2023, Investigational New Drugs.

Characterization of bone only metastasis patients with respect to tumor subtypes

G. Hortobagyi, C. Warneke, J. Litton, 2018, npj Breast Cancer.

A phase II study of neoadjuvant atezolizumab and nab-paclitaxel in patients with anthracycline-resistant early-stage triple-negative breast cancer

W. Symmans, V. Valero, N. Ibrahim, 2023, Breast Cancer Research and Treatment.

Comparison of attitudes regarding preimplantation genetic diagnosis among patients with hereditary cancer syndromes

L. Schover, B. Arun, K. Lu, 2014, Familial Cancer.

Neoadjuvant talazoparib (TALA) in patients (pts) with germline BRCA1/2 (gBRCA1/2) mutation-positive, early HER2-negative breast cancer (BC): Exploration of tumor BRCA mutational status and zygosity and overall mutational landscape in a phase 2 study.

W. Symmans, M. Danso, A. Abbattista, 2021 .

Phase I trial of olaparib (PARP inhibitor) and vistusertib (mTORC1/2 inhibitor) in recurrent endometrial, ovarian and triple negative breast cancer.

G. Mills, V. Valero, A. Sood, 2018 .

Standardized Definitions for Efficacy End Points in Neoadjuvant Breast Cancer Clinical Trials: NeoSTEEP

J. Foster, W. Woodward, L. Pusztai, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A feasibility study of neoadjuvant talazoparib for operable breast cancer patients with a germline BRCA mutation demonstrates marked activity

G. Mills, K. Hess, V. Valero, 2017, npj Breast Cancer.

P2-13-05: Breast Cancer, BRCA Mutations and Attitudes Regarding Pregnancy and Preimplantation Genetic Diagnosis.

G. Hortobagyi, R. Theriault, L. Schover, 2011 .

Active Disclosure of Secondary Germline Findings to Deceased Research Participants' Personal Representatives: Process and Outcomes.

G. Mills, L. Strong, F. Meric-Bernstam, 2017, JCO precision oncology.

Incidence, risk factors, and obstetrical outcomes of women with breast cancer in pregnancy: Abenhaim HA, Azoulay L, Holcroft CA, et al (McGill Univ, Montreal, Canada; Jewish General Hosp, Montreal, Quebec, Canada) Breast J 18:564-568, 2012

J. Litton, 2013 .

Genetic/familial high-risk assessment: breast and ovarian.

S. Gruber, S. Friedman, K. Offit, 2010, Journal of the National Comprehensive Cancer Network : JNCCN.

Neoadjuvant talazoparib in patients with germline BRCA1/2 (gBRCA1/2) mutation-positive, early HER2-negative breast cancer (BC): Results of a phase 2 study.

W. Symmans, J. Chakrabarti, M. Danso, 2021, Journal of Clinical Oncology.

Genetic/familial high-risk assessment

L. Esserman, S. Friedman, K. Offit, 2010 .

PTEN in triple-negative breast carcinoma: protein expression and genomic alteration in pretreatment and posttreatment specimens

Jeffrey T. Chang, W. Symmans, V. Valero, 2023, Therapeutic advances in medical oncology.

Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version

K. Offit, S. Buys, Rashmi Kumar, 2014 .

SETER/PR: a robust 18-gene predictor for sensitivity to endocrine therapy for metastatic breast cancer

A. Viale, C. Sotiriou, W. Fraser Symmans, 2019, npj Breast Cancer.

Genetic/familial high-risk assessment: breast and ovarian, version 1.2014.

S. Friedman, K. Offit, S. Buys, 2014, Journal of the National Comprehensive Cancer Network : JNCCN.

NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020

S. Friedman, K. Offit, S. Buys, 2020, Journal of the National Comprehensive Cancer Network.

Prevention of everolimus/exemestane (EVE/EXE) stomatitis in postmenopausal (PM) women with hormone receptor-positive (HR+) metastatic breast cancer (MBC) using a dexamethasone-based mouthwash (MW): Results of the SWISH trial.

M. Chambers, H. Rugo, T. Pluard, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Breast radiotherapy-related treatment outcomes in patients with or without germline mutations on multigene panel testing.

Diane D. Liu, W. Woodward, Benjamin D. Smith, 2021, International journal of radiation oncology, biology, physics.

Tumor immune microenvironment changes by multiplex immunofluorescence staining in a pilot study of neoadjuvant talazoparib for early-stage breast cancer patients with a hereditary BRCA mutation.

Jeffrey T. Chang, Fei Yang, Yiling Lu, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

A Radiomics Model Based on Synthetic MRI Acquisition for Predicting Neoadjuvant Systemic Treatment Response in Triple-Negative Breast Cancer.

K. Hwang, G. Rauch, B. Adrada, 2023, Radiology. Imaging cancer.

Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2015.

S. Friedman, K. Offit, S. Buys, 2016, Journal of the National Comprehensive Cancer Network : JNCCN.

Cancer and Pregnancy

J. Litton, 2019, Holland‐Frei Cancer Medicine.

Deep Learning for Fully Automatic Tumor Segmentation on Serially Acquired Dynamic Contrast-Enhanced MRI Images of Triple-Negative Breast Cancer

B. Adrada, Jingfei Ma, R. Candelaria, 2023, Cancers.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Charles J. Vaske, Joe Y. Chang, Scott R. Presnell, 2016, Journal for ImmunoTherapy of Cancer.

Outcome of metastatic breast cancer in selected women with or without deleterious BRCA mutations

G. Hortobagyi, V. Valero, N. Ibrahim, 2013, Clinical & Experimental Metastasis.

Response to neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers: a single-institution experience.

Diane D. Liu, G. Hortobagyi, L. Pusztai, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Age and survival estimates in patients who have node-negative T1ab breast cancer by breast cancer subtype.

W. Woodward, G. Hortobagyi, F. Meric-Bernstam, 2011, Clinical breast cancer.

Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial.

C. Isaacs, Bing-he Xu, F. André, 2014, The Lancet. Oncology.

A phase 1b/2 study of the BET inhibitor ZEN-3694 in combination with talazoparib for treatment of patients with TNBC without gBRCA1/2 mutations.

M. Robson, S. Domchek, S. Attwell, 2022, Journal of Clinical Oncology.

MRI-based digital models forecast patient-specific treatment responses to neoadjuvant chemotherapy in triple-negative breast cancer.

T. Yankeelov, V. Valero, G. Rauch, 2022, Cancer research.

Predicting pathological complete response to neoadjuvant systemic therapy for triple-negative breast cancers using deep learning on multiparametric MRIs

Tanya W. Moseley, G. Rauch, M. Scoggins, 2023, 2023 45th Annual International Conference of the IEEE Engineering in Medicine & Biology Society (EMBC).

Subgroup efficacy evaluation of the AE37 HER2 vaccine in breast cancer patients in the adjuvant setting.

E. Mittendorf, G. Peoples, J. Litton, 2017 .

Comparison of attitudes regarding preimplantation genetic diagnosis among patients with hereditary cancer syndromes

L. Schover, B. Arun, K. Ready, 2013, Familial Cancer.

Short-Term Biomarker Modulation Study of Dasatinib for Estrogen Receptor-Negative Breast Cancer Chemoprevention.

N. Sneige, D. Booser, J. Litton, 2023, European journal of breast health.

Predictive Roles of Baseline Stromal Tumor-Infiltrating Lymphocytes and Ki-67 in Pathologic Complete Response in an Early-Stage Triple-Negative Breast Cancer Prospective Trial

W. Symmans, V. Valero, N. Ibrahim, 2023, Cancers.

Prognostic Impact of High Baseline Stromal Tumor-Infiltrating Lymphocytes in the Absence of Pathologic Complete Response in Early-Stage Triple-Negative Breast Cancer

Jeffrey T. Chang, W. Symmans, V. Valero, 2022, Cancers.

Utility of oncotype DX risk estimates in clinically intermediate risk hormone receptor‐positive, HER2‐normal, grade II, lymph node‐negative breast cancers

G. Hortobagyi, L. Pusztai, S. Krishnamurthy, 2010, Cancer.